-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Benzinga·06/23/2026 16:35:13
Listen to the news
HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.